DDrare: Database of Drug Development for Rare Diseases

260. シトステロール血症
［臨床試験数：13，薬物数：13（DrugBank：4），標的遺伝子数：1，標的パスウェイ数：1］

Searched query = "Sitosterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Behavioral: High/Low Sitosterol; Colesevelam; Combination of fish oil and colesevelam; Comparator: ezetimibe; Ezetimibe; Ezetimibe + other lipid-lowering medication(s); Ezetrol; Fish Oil; Fish oil; MK-0653; MK0653, ezetimibe; SCH-58235; Sitosterol

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00092833 (ClinicalTrials.gov)	July 2002	23/9/2004	Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)	An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia	Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors	Drug: Comparator: ezetimibe	Merck Sharp & Dohme Corp.	NULL	Terminated	8 Years	N/A	All	49	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00092833
(ClinicalTrials.gov)

July 2002

23/9/2004

Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)

An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia

Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors

Drug: Comparator: ezetimibe

Merck Sharp & Dohme Corp.

NULL

Terminated

8 Years

N/A

All

Phase 3

United States